Who is sponsoring NCT06008795?

NCT06008795 is sponsored by University of Florida.

What condition does NCT06008795 study?

NCT06008795 studies Subarachnoid Hemorrhage, Aneurysmal, Headache.

Is NCT06008795 still recruiting?

NCT06008795 is currently recruiting now. Last updated 28 November 2025.

Last reviewed 2025-11-28 · How we verify

NCT06008795: BLOCK-SAH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BLOCK-SAH - PPF-Block for Post-SAH Headache

Recruiting now Phase 2 Last updated 28 November 2025

What this trial tests

Phase 2 trial testing Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone in Subarachnoid Hemorrhage, Aneurysmal in 195 participants. Currently enrolling.

Timeline

17 December 2023

Primary endpoint
15 January 2027

28 February 2027

Quick facts

Lead sponsor	University of Florida
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Enrollment	195
Start date	17 December 2023
Primary completion	15 January 2027
Estimated completion	28 February 2027
Sites	11 locations across United States

Drugs / interventions tested

Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone — full drug profile →
Placebo Pteryogpalatine Fossa Injection

Conditions studied

Subarachnoid Hemorrhage, Aneurysmal — all drugs for Subarachnoid Hemorrhage, Aneurysmal →
Headache — all drugs for Headache →

Sponsor

University of Florida

Who can join

Adults 18 to 85, any sex, with Subarachnoid Hemorrhage, Aneurysmal or Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to saline (placebo) for headache in survivors of aneurysmal subarachnoid hemorrhage (SAH), while monitoring intracranial arterial mean flow velocities with transcranial Doppler (TCD) peri-intervention (intervention = PPF-injections: active or placebo)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Rationale and Design for the BLOCK-SAH Study (Pterygopalatine Fossa Block as an Opioid-Sparing Treatment for Acute Headache in Aneurysmal Subarachnoid Hemorrhage): A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial with a Sequential Parallel Co
Busl KM, Smith CR, Troxel AB, Fava M, et al · · 2025 · cited 5× · PMID 39138719 · DOI 10.1007/s12028-024-02078-z
Beyond the bleed: complications after aneurysmal subarachnoid hemorrhage. Pathophysiology, clinical implications, and management strategies: a review.
Busl KM, Bogossian EG, Claassen J, Helbok R, et al · · 2025 · cited 4× · PMID 41029753 · DOI 10.1186/s13054-025-05640-z

Verify or expand the search:

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage · Phase 2 · recruiting
NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H · NA · recruiting
NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction · recruiting
NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage · recruiting
NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage · recruiting

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06008795 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 28 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06008795.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing